期刊文献+

低剂量FLAG方案治疗难治性老年人急性髓系白血病12例 被引量:2

原文传递
导出
摘要 目的探讨低剂量FLAG方案治疗难治性老年人急性髓系白血病(AML)的临床疗效。方法应用FLAG方案即氟达拉滨(Flud)30mg·m^-2·d^-1静脉滴注,第1天至第5天;间隔4h后给予阿糖胞苷(Ara—C)0.35g.m^-2·d^-1静脉滴注.第1天至第5天;粒细胞集落刺激因子(G—CSF)200ug·m^-2·d^-1皮下注射.第0天至第5天.治疗难治性老年人AML12例。结果2例患者获得完全缓解(CR),1例患者获得部分缓解(PR),总有效率(CR+PR)25%,毒副作用为白细胞、血小板减少、继发感染、发热等。结论FLAG方案治疗难治性老年人AML较其他方案疗效相当,可进一步探讨Ara—C的恰当用量,以提高其疗效。
出处 《白血病.淋巴瘤》 CAS 2008年第6期457-459,共3页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献8

二级参考文献31

  • 1欧阳建,白荣森.55例老年人急性白血病治疗观察[J].中华老年医学杂志,1996,15(4):211-213. 被引量:19
  • 2Lamanna N, Weiss M. Purine analogs in leukemia. Adv Pharmacol,2004, 51:107-125.
  • 3Milligan DW, Wheatley K, Burnett AK. Fludarabine, cytosine arabiuoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol, 2004,127:238-239.
  • 4Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol, 2003, 82:231-235.
  • 5Hanel M, Friedrichsen K, Hanel A, et al. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie,2001, 24:356-360.
  • 6Russo D, Pricolo G, Michieli M, et al. Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia. Leuk Lymphoma, 2001,40:335-343.
  • 7Jackson G, Taylor P, Smith GM, et al. A multicentre, open, noncomparative phase Ⅱ study of a combination of fludarabine phosphate,cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol, 2001, 112:127-137.
  • 8Bai A, Kojima H, Hori M, et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol, 1999, 27:259-265.
  • 9Hubeek I, Litvinova E, Peters GJ, et al. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. Int J Oncol, 2004, 25:1823-1829.
  • 10Estey EH, Thall PF, Pierce S, et al. Randomized phase Ⅱ study of fludarabine + cytosine arabinoside + idarubicin + /- all-trans retinoic acid + / - granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood, 1999, 93:2478-2484.

共引文献96

同被引文献13

  • 1Godwin J.Design and conduct of a double-blind,placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colong-stimulating factor in elderly patients with acute myeloid lcukemia:a southwest oncology group study. J Natl Cancer lnst Monogr, 1995, 19:31.
  • 2Copplestone JA, Smith AG. Acute myeloid leulemia in the elderly. Leuk Res, 1988,12:617-625.
  • 3Stone RM. The difficult problem of acute myeloid leukema in the alder adult. CA Cancer J Clin, 2002,52:363-371.
  • 4Yamada K, Furusawa S, Saito K,et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubingcin for previously treated acute myelogenous leukemia pilot study. Leukamia, 1995,9:10- ! 4.
  • 5Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combinalion with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia(AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol, 2000,71:238-244.
  • 6Bai A, Kojima H, Hori M, et al. Priming with G-CSF effectively enhances low-dose Ara-C-cinduced in vivo apoltosis in myeloid leukemia cells. Exp Hematol, 1999, 27:259-265.
  • 7Issa JP, Garcia-Manero G, Giles FJ, et al. Phase I study of low-dose prolonged exposure schedules of the hypometylating agent 5-aza-2 - deoxycytidine (decitabine)in hematopoieticmalignancies. Blood, 2004, 103: 1635-1640.
  • 8Kantarian HO, Brien S, Giles F, et al. Decitabine low dose Schedule (100 mg/m2/coume) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules. 2010 ASH, Annual Meeting Abstract 2522.
  • 9上海市白血病协作组.上海地区老年急性白血病417例回顾性研究[J].中华血液学杂志,1998,19(1):3-5. 被引量:83
  • 10高冲,陈宝安,刘苒,徐昕,丁家华,王骏,程坚,赵刚,余正平,宋慧慧,鲍文.地西他滨治疗骨髓增生异常综合征一例报告[J].现代医学,2010,38(2):189-190. 被引量:10

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部